Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 1/20 | 0.57 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.53 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.53 |
| ▸ | DPP4 | P27487 | 3/20 | 0.49 |
| ▸ | SLC7A5 | Q01650 | 2/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.47 |
| ▸ | ALPI | P09923 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | XIAP | P98170 | 1/20 | 0.47 |
| ▸ | CTSC | P53634 | 1/20 | 0.47 |
| ▸ | PPARG | P37231 | 1/20 | 0.46 |
| ▸ | PPARA | Q07869 | 1/20 | 0.46 |
| ▸ | FAP | Q12884 | 1/20 | 0.46 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.46 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.46 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.46 |
| ▸ | TPH1 | P17752 | 1/20 | 0.45 |
| ▸ | ACACB | O00763 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8122168 | 1.00 | SLC6A4 (0.57) | SLC6A4SLC6A3SLC6A2DPP4SLC7A5 | |
| SCHEMBL6317469 | 1.00 | SLC6A4 (0.57) | SLC6A4SLC6A3SLC6A2DPP4SLC7A5 | |
| Hydrochloric Acid SCHEMBL8335060 | 0.98 | SLC6A4 (0.55) | SLC6A4SLC6A3SLC6A2DPP4SLC7A5 | |
| Fenclonine SCHEMBL26382 | 0.84 | SLC7A5 (0.69) | SLC6A4SLC6A3SLC6A2SLC7A5PTGS1 | |
| SCHEMBL4654874 | 0.84 | SLC6A2 (0.59) | SLC6A4SLC6A3SLC6A2DPP4SLC7A5 | |
| Fenclonine SCHEMBL26383 | 0.84 | SLC7A5 (0.69) | SLC6A4SLC6A3SLC6A2SLC7A5PTGS1 | |
| Fenclonine SCHEMBL3140768 | 0.84 | SLC7A5 (0.69) | SLC6A4SLC6A3SLC6A2SLC7A5PTGS1 | |
| SCHEMBL12104067 | 0.84 | SLC6A2 (0.59) | SLC6A4SLC6A3SLC6A2DPP4SLC7A5 | |
| SCHEMBL12188513 | 0.84 | SLC6A2 (0.59) | SLC6A4SLC6A3SLC6A2DPP4SLC7A5 | |
| Fenclonine SCHEMBL245828 | 0.84 | SLC7A5 (0.69) | SLC6A4SLC6A3SLC6A2SLC7A5PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1589403-B | Methods of assaying connective tissue growth factor | FIBROGEN INC | 2011-06-01 | — | — | CN | disclosed |
| US-20080207677-A1 | Napthyridine Compounds As Rock Inhibitors | GPC BIOTECH AG (DE) | 2008-08-28 | — | — | US | disclosed |
| US-6949658-B2 | Process for producing optically active α-amino acid and optically active α-amino acid amide | MITSUBISHI RAYON CO., LTD. (JP) | 2005-09-27 | — | — | US | disclosed |
| CN-1589403-A | Methods of assaying connective tissue growth factor | FIBROGEN INC (US) | 2005-03-02 | — | — | CN | disclosed |
| US-20030171597-A1 | Process for producing optically active alpha-amino acid and optically active alpha-amino acid amine | MITSUBISHI RAYON CO., LTD. (JP) | 2003-09-11 | — | — | US | disclosed |
| EP-1300392-A1 | PROCESS FOR PRODUCING OPTICALLY ACTIVE ALPHA-AMINO ACID AND OPTICALLY ACTIVE ALPHA-AMINO ACID AMIDE | Mitsubishi Rayon Co., Ltd. (JP) | 2003-04-09 | — | — | EP | disclosed |
| EP-0495013-B1 | HEXAPEPTIDES WITH SULPHATE ESTER GROUPS | FISONS CORP (US) | 1995-03-08 | — | — | EP | disclosed |
| EP-0226217-B1 | Peptides with sulfate ester group | FISONS CORP (US) | 1994-01-26 | — | — | EP | disclosed |
| EP-0495013-A1 | HEXAPEPTIDES WITH SULPHATE ESTER GROUPS. | FISONS CORP (US) | 1992-07-22 | — | — | EP | disclosed |
| WO-1991008225-A1 | HEXAPEPTIDES WITH SULPHATE ESTER GROUPS | FISONS CORPORATION (US) | 1991-06-13 | — | — | WO | disclosed |
| EP-0193083-A1 | Anti-tumoral(1-arylmethyl-ethylene diamine)-platinum(II)-complexes | ASTA Pharma AG (DE) | 1986-09-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030171597-A1 | Process for producing optically active alpha-amino acid and optically active alpha-amino acid amine | AADAT, BCAT1, BCAT2 | SLC6A4 1580/4885SLC6A3 1676/4885SLC6A2 1564/4885 |
| US-20080207677-A1 | Napthyridine Compounds As Rock Inhibitors | ROCK2, ROCK1, RHOT2 | SLC6A4 426/4885SLC6A3 487/4885SLC6A2 49/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.